Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 107

1.

Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.

Muqbil I, Chaker M, Aboukameel A, Mohammad RM, Azmi AS, Ramchandren R.

Heliyon. 2019 Aug 31;5(8):e02290. doi: 10.1016/j.heliyon.2019.e02290. eCollection 2019 Aug.

2.

DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma.

Azmi AS, Li Y, Aboukameel A, Muqbil I, Philip PA, Mohammad RM.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1101. doi: 10.3390/cancers11081101.

3.

Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation.

Siveen KS, Prabhu KS, Parray AS, Merhi M, Arredouani A, Chikri M, Uddin S, Dermime S, Mohammad RM, Steinhoff M, Janahi IA, Azizi F.

Sci Rep. 2019 Feb 7;9(1):1554. doi: 10.1038/s41598-018-37469-8.

4.

Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells.

Teslow EA, Mitrea C, Bao B, Mohammad RM, Polin LA, Dyson G, Purrington KS, Bollig-Fischer A.

Mol Oncol. 2019 Apr;13(4):894-908. doi: 10.1002/1878-0261.12444. Epub 2019 Mar 1.

5.

Anticancer Activity of Camel Milk via Induction of Autophagic Death in Human Colorectal and Breast Cancer Cells

Krishnankutty R, Iskandarani A, Therachiyil L, Uddin S, Azizi F, Kulinski M, Bhat AA, Mohammad RM.

Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3501-3509.

6.

Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study.

Ennkaa A, Shaath N, Salam A, Mohammad RM.

Turk J Gastroenterol. 2018 Sep;29(5):549-554. doi: 10.5152/tjg.2018.17707.

7.

Nuclear Export Inhibition for Pancreatic Cancer Therapy.

Muqbil I, Azmi AS, Mohammad RM.

Cancers (Basel). 2018 May 7;10(5). pii: E138. doi: 10.3390/cancers10050138. Review.

8.

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.

Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA, Mohammad RM.

Oncotarget. 2017 Jul 17;8(47):82144-82155. doi: 10.18632/oncotarget.19285. eCollection 2017 Oct 10.

9.

Dysregulated expression of SKP2 and its role in hematological malignancies.

Kulinski M, Achkar IW, Haris M, Dermime S, Mohammad RM, Uddin S.

Leuk Lymphoma. 2018 May;59(5):1051-1063. doi: 10.1080/10428194.2017.1359740. Epub 2017 Aug 10. Review.

PMID:
28797197
10.

Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells.

Prabhu KS, Siveen KS, Kuttikrishnan S, Iskandarani A, Tsakou M, Achkar IW, Therachiyil L, Krishnankutty R, Parray A, Kulinski M, Merhi M, Dermime S, Mohammad RM, Uddin S.

PLoS One. 2017 Jul 13;12(7):e0180895. doi: 10.1371/journal.pone.0180895. eCollection 2017.

11.

Molecular genetic analysis of consanguineous families with primary microcephaly identified pathogenic variants in the ASPM gene.

Khan MA, Windpassinger C, Ali MZ, Zubair M, Gul H, Abbas S, Khan S, Badar M, Mohammad RM, Nawaz Z.

J Genet. 2017 Jun;96(2):383-387.

12.

Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.

Mohammad RM, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Philip PA, Azmi AS.

Small GTPases. 2019 Sep;10(5):367-377. doi: 10.1080/21541248.2017.1329694. Epub 2017 Jun 23.

PMID:
28641032
13.

Anticancer potential of sanguinarine for various human malignancies.

Achkar IW, Mraiche F, Mohammad RM, Uddin S.

Future Med Chem. 2017 Jun;9(9):933-950. doi: 10.4155/fmc-2017-0041. Epub 2017 Jun 21. Review.

PMID:
28636454
14.

Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.

Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, Polin L, Dyson G, Taub JW, Mohammad RM, Azmi AS, Zhao L, Ge Y.

Oncotarget. 2017 Jul 4;8(27):44295-44311. doi: 10.18632/oncotarget.17869.

15.

Potential therapeutic targets of Guggulsterone in cancer.

Bhat AA, Prabhu KS, Kuttikrishnan S, Krishnankutty R, Babu J, Mohammad RM, Uddin S.

Nutr Metab (Lond). 2017 Feb 28;14:23. doi: 10.1186/s12986-017-0180-8. eCollection 2017. Review.

16.

Targeting acute myeloid leukemia stem cell signaling by natural products.

Siveen KS, Uddin S, Mohammad RM.

Mol Cancer. 2017 Jan 30;16(1):13. doi: 10.1186/s12943-016-0571-x. Review.

17.

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.

Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS.

Mol Cancer Ther. 2017 Jan;16(1):76-87. doi: 10.1158/1535-7163.MCT-16-0205. Epub 2016 Nov 15.

18.

Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges.

Siveen KS, Prabhu K, Krishnankutty R, Kuttikrishnan S, Tsakou M, Alali FQ, Dermime S, Mohammad RM, Uddin S.

Curr Vasc Pharmacol. 2017;15(4):339-351. doi: 10.2174/1570161115666170105124038. Review.

PMID:
28056756
19.

The Molecular Genetics of Autosomal Recessive Nonsyndromic Intellectual Disability: a Mutational Continuum and Future Recommendations.

Khan MA, Khan S, Windpassinger C, Badar M, Nawaz Z, Mohammad RM.

Ann Hum Genet. 2016 Nov;80(6):342-368. doi: 10.1111/ahg.12176. Review.

20.

Targeting Cancer at the Nuclear Pore.

Azmi AS, Mohammad RM.

J Clin Oncol. 2016 Dec;34(34):4180-4182. Epub 2016 Oct 23. No abstract available.

PMID:
27863200

Supplemental Content

Loading ...
Support Center